Cogent Biosciences is trading higher as the market continues to price in a clearer regulatory path for bezuclastinib in non-advanced systemic mastocytosis (NonAdvSM). The latest key catalyst in the tape is the FDA’s acceptance of Cogent’s New Drug Application for bezuclastinib, including a December 30, 2026 action date and an initial review that did not flag review issues or an advisory committee plan at this stage. (simplywall.st)

Beyond the regulatory acceptance, investors are leaning into evidence that the drug’s symptomatic benefit may deepen over time. The pivotal SUMMIT study met primary and key secondary endpoints, and the reported symptomatic improvement continuing through 48 weeks supports a chronic-use profile in a high unmet-need population—an attribute that can materially change long-term revenue expectations if the label and payer dynamics cooperate. (simplywall.st)

The next major swing factor is execution between now and the FDA decision date, including ongoing clinical and commercial-readiness milestones and whether any additional regulatory steps emerge (such as a later-announced advisory committee). With the stock already reflecting optimism around bezuclastinib, investors are likely to react quickly to any updates that change perceived approval probability, timeline, or launch readiness. (simplywall.st)